Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Osimertinib
57%
Epidermal Growth Factor Receptor
55%
Immune Checkpoint Inhibitor
45%
Progression Free Survival
39%
Chemotherapy
35%
Lung Cancer
30%
Monotherapy
27%
Docetaxel
25%
Overall Survival
24%
Pembrolizumab
21%
Afatinib
21%
Programmed Death 1 Ligand 1
20%
Neoplasm
19%
Paclitaxel
17%
Cohort Study
15%
Disease
13%
Epidermal Growth Factor Receptor Kinase Inhibitor
12%
Programmed Cell Death
12%
Pneumonia
10%
Combination Therapy
9%
Protein P53
9%
Carboplatin
8%
Observational Study
8%
Adverse Event
8%
Creatinine
8%
Phase II Trials
8%
Retrospective Study
7%
Pemetrexed
7%
Chemoradiation Therapy
7%
Health Care Associated Pneumonia
7%
Proton Pump Inhibitor
7%
Cachexia
7%
Pleura Mesothelioma
7%
Liver Cell Carcinoma
7%
Antibiotic Agent
7%
Antibiotics
7%
Erlotinib
7%
Epidermal Growth Factor
7%
Nivolumab
7%
Ramucirumab
7%
Durvalumab
7%
Immunotherapy
7%
Homeobox Protein Nkx 2.1
7%
Malignant Neoplasm
6%
Survival Rate
6%
Vasculotropin C
5%
Glucose Regulated Protein
5%
Biological Marker
5%
Medicine and Dentistry
Non Small Cell Lung Cancer
62%
Chemoimmunotherapy
32%
Immune Checkpoint Inhibitor
29%
Osimertinib
28%
Monotherapy
23%
Retrospective Study
21%
Endobronchial Ultrasonography
21%
Transbronchial Biopsy
21%
Epidermal Growth Factor Receptor
20%
Lung Cancer
16%
Progression Free Survival
14%
Programmed Cell Death
14%
Combination Therapy
12%
Epidermal Growth Factor Receptor Kinase Inhibitor
11%
Neoplasm
11%
Maintenance Therapy
11%
Non-Small Cell Lung Cancer
9%
Programmed Death 1 Ligand 1
8%
Pneumothorax
8%
Liver Metastasis
8%
Immunohistochemistry
7%
Peripheral Lung Lesion
7%
Overall Survival
7%
Bronchial Thermoplasty
7%
Protein P53
7%
Health Care Associated Pneumonia
7%
Respiratory Failure
7%
Pembrolizumab
7%
Carcinoma
7%
Mediastinal Lymphadenopathy
7%
Cachexia
7%
Bronchus Obstruction
7%
Curette
7%
Amrubicin
7%
Confocal Laser Scanning Microscopy
7%
Continuous Ambulatory Peritoneal Dialysis
7%
Gefitinib
7%
Pharmacokinetics
7%
Small Cell Lung Cancer
7%
Cohort Analysis
7%
Epidermal Growth Factor
7%
Glucose Transporter 1
7%
Amino Acid Transporter
7%
Pneumonia
7%
Thymoma
7%
Mycoplasma Pneumonia
7%
Biopsy
7%
Asthma
7%
Cancer Chemotherapy
7%
Lung Alveolus Proteinosis
7%
Keyphrases
Non-small Cell Lung Cancer (NSCLC)
39%
Immune Checkpoint Inhibitors
32%
Programmed Death-ligand 1 (PD-L1)
29%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
25%
Monotherapy
21%
Osimertinib
16%
Phase II Trial
15%
Chemotherapy
15%
Pembrolizumab
14%
Previously Treated
14%
Pulmonary Pleomorphic Carcinoma
14%
Tumor Proportion Score
12%
Confidence Interval
12%
Docetaxel
11%
Chemoimmunotherapy
11%
Epidermal Growth Factor Receptor
9%
Progression-free Survival
9%
Overall Survival
8%
Without Chemotherapy
8%
Performance Status
8%
Clinical Factors
8%
Nab-paclitaxel
7%
Prognostic Impact
7%
Lung Immune Prognostic Index
7%
Induction Immunochemotherapy
7%
Chemoradiotherapy
7%
Cancer Cell Death
7%
Peripheral Lung Lesion
7%
Clinical Features
7%
Bronchus Sign
7%
Transbronchial Biopsy
7%
Endobronchial Ultrasound with a Guide Sheath
7%
Tyrosine Kinase Inhibitor Therapy
7%
Proton Pump Inhibitors
7%
Sleep Apnea Syndrome
7%
Healthcare-associated Pneumonia
7%
Carboplatin Dosing
7%
Glucose Transporter 1 (GLUT1)
7%
Usual Interstitial Pneumonia Pattern
7%
Albumin Paclitaxel
7%
Lymphocyte Profile
7%
Mediastinal Lymphadenopathy
7%
Poor Performance Status
7%
Epigenetic Profile
7%
Afatinib
7%
Activating EGFR mutation
7%
Silicone Spigot
7%
Endobronchial Watanabe Spigot
7%
Curette
7%
Cancer Analysis
7%